L-Kynurenine
(Synonyms: L-犬尿氨酸) 目录号 : GC12040L-Kynurenine是L-色氨酸的代谢物,也是一种芳香烃受体 (aryl hydrocarbon receptor; AhR) 激动剂。
Cas No.:2922-83-0
Sample solution is provided at 25 µL, 10mM.
L-Kynurenine is a metabolite of L-tryptophan and an aryl hydrocarbon receptor (AhR) agonist. L-Kynurenine can also cause NK cell death through the reactive oxygen species (ROS) pathway[1][2].
L-Kynurenine triggers competition between aryl hydrocarbon receptor and hypoxia-inducible factor 1 alpha (HIF-1α) for ARNT (Aryl Hydrocarbon Receptor Nuclear Translocator) in MCF-7 cells under hypoxic conditions [1]. L-Kynurenine (0-1mM; 48h) specifically affects the expression of NKp46, NKG2D, and CD69 in the phenotype of NK cells cultured in IL-2, without altering the surface density of other triggering or coreceptors, including CD16, 2B4, NTB-A, DNAM-1, and CD59, or the surface density of inhibitory receptors[2]. After adding L-Kynurenine (10-40µM) to the supernatant of HCEC cells, cell apoptosis increased slightly and had a certain dose-dependent toxicity [3]. Treatment with L-Kynurenine (0–800μM; 72h) dose-dependently induced growth inhibition and apoptosis in NK92 MI cells[4].
L-Kynurenine (30mg/kg) inhibited ischemia-induced hyperlocomotion in the mouse MCAO model and reduced ischemia-induced deterioration of spontaneous alternation (a measure of spatial memory) without changing rectal temperature[5]. In the rat L5/L6 spinal nerve ligation model, L-Kynurenine (50-200mg/kg; ip) did not affect allodynia in neuropathic rats, while the combination of L-Kynurenine and the organic anion transport inhibitor probenecid (100mg/kg; ip) reversed allodynia[6].
References:
[1]. Cuartero M I, Ballesteros I, de la Parra J, et al. L-kynurenine/aryl hydrocarbon receptor pathway mediates brain damage after experimental stroke[J]. Circulation, 2014, 130(23): 2040-2051.
[2]. Schlichtner S, Yasinska I M, Klenova E, et al. L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes[J]. OncoImmunology, 2023, 12(1): 2244330.
[3]. Chiesa M D, Carlomagno S, Frumento G, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function[J]. Blood, 2006, 108(13): 4118-4125.
[4]. Serbecic N, Lahdou I, Scheuerle A, et al. Function of the tryptophan metabolite, L-kynurenine, in human corneal endothelial cells[J]. Molecular vision, 2009, 15: 1312.
[5]. Gigler G, Szénási G, Simó A, et al. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils[J]. European journal of pharmacology, 2007, 564(1-3): 116-122.
[6]. Pineda‐Farias J B, Pérez‐Severiano F, González‐Esquivel D F, et al. The l‐kynurenine–probenecid combination reduces neuropathic pain in rats[J]. European journal of pain, 2013, 17(9): 1365-1373.
L-Kynurenine是L-色氨酸的代谢物,也是一种芳香烃受体 (aryl hydrocarbon receptor; AhR) 激动剂[1][2]。
在缺氧条件下,L-Kynurenine会引发芳香烃受体和缺氧诱导因子1α(HIF-1α)竞争MCF-7细胞中的ARNT(Aryl Hydrocarbon Receptor Nuclear Translocator,芳基烃受体核转位子)[1]。L-Kynurenine(0-1mM;48h)特异性影响在IL-2中培养的NK细胞表型中NKp46、NKG2D和CD69的表达,而不会改变其他触发或辅助受体的表面密度,包括CD16、2B4、NTB-A、DNAM-1和CD59,或抑制性受体的表面密度[2]。HCEC细胞上清液中加入L-Kynurenine(10-40µM)后,细胞凋亡略有增加,并具有一定的剂量依赖性毒性[3]。L-Kynurenine(0-800μM;72h)处理NK92 MI细胞,可剂量依赖性地诱导生长抑制和细胞凋亡[4]。
L-Kynurenine(30mg/kg)在不改变直肠温度的条件下抑制了小鼠MCAO模型中缺血引起的运动亢进,并降低了缺血引起的自发交替恶化(一种空间记忆的衡量标准)[5]。在大鼠L5/L6脊神经结扎模型中,L-Kynurenine(50-200mg/kg;ip)不影响神经病大鼠的异常性疼痛,而L-Kynurenine和有机阴离子转运抑制剂丙磺舒(100mg/kg;ip)联合使用可逆转异常性疼痛[6]。
Cell experiment [1]: | |
Cell lines | MCF-7 human breast cancer cells |
Preparation Method | MCF-7 human breast cancer cells were exposed to 50µM L-Kynurenine for 4h under normal (21%) or low (1%) oxygen supply conditions. |
Reaction Conditions | 50µM; 4h |
Applications | L-Kynurenine triggers competition between aryl hydrocarbon receptor (AhR) and hypoxia-inducible factor 1 alpha (HIF-1α) for ARNT in cells under hypoxic conditions. |
Animal experiment [2]: | |
Animal models | Middle cerebral artery occlusion (MCAO) Modle |
Preparation Method | Mice were injected with L-Kynurenine (30mg/kg) 15min before MCAO surgery, and the neuroprotective effects of L-Kynurenine sulfate (a precursor of kynurenic acid) were measured 24 to 48h later. |
Dosage form | 30mg/kg; ip |
Applications | L-Kynurenine inhibited the ischemia-induced hypermotility, and decreased the ischemia-induced deterioration of spontaneous alternation, a measure of spatial memory, without altering the rectal temperature. |
References: |
Cas No. | 2922-83-0 | SDF | |
别名 | L-犬尿氨酸 | ||
化学名 | (2S)-2-amino-4-(2-aminophenyl)-4-oxobutanoic acid | ||
Canonical SMILES | C1=CC=C(C(=C1)C(=O)CC(C(=O)O)N)N | ||
分子式 | C10H12N2O3 | 分子量 | 208.21 |
溶解度 | ≥ 10.85mg/mL in Water with gentle warming | 储存条件 | Store at RT |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.8028 mL | 24.0142 mL | 48.0284 mL |
5 mM | 0.9606 mL | 4.8028 mL | 9.6057 mL |
10 mM | 0.4803 mL | 2.4014 mL | 4.8028 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet